Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Study Information
Alliance Study ID: CALGB-90206
NCT Study ID (ClinicalTrials.gov): NCT00072046
Alliance Committee: Genitourinary Cancer
Disease or Cancer Type: Genitourinary Cancers – Kidney / Bladder / Urothelial / Testicular
Alliance Study Chair: Brian I. Rini, MD
Status: COMPLETED
Study Description
RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether interferon alfa-2b is more effective with or without bevacizumab in treating advanced renal cell carcinoma (kidney cancer).
PURPOSE: This randomized phase III trial is studying interferon alfa-2b and bevacizumab to see how well they work compared to interferon alfa-2b alone in treating patients with advanced renal cell carcinoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information